# Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

> **NCT06585020** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 190 (estimated)

## Conditions studied

- Mycobacterium; Xenopi
- Lung Diseases

## Interventions

- **DRUG:** Arikayce
- **DRUG:** standard treatment

## Key facts

- **NCT ID:** NCT06585020
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-20
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585020, "Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06585020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*